347 related articles for article (PubMed ID: 18785508)
1. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
[TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Stasi R; Pagano A; Stipa E; Amadori S
Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
10. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
11. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
Tanai C; Iki S; Nakahara F; Iijima K; Usuki K; Kuwana M; Urabe A
Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
[TBL] [Abstract][Full Text] [Related]
12. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
13. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
[TBL] [Abstract][Full Text] [Related]
14. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
15. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
[TBL] [Abstract][Full Text] [Related]
18. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]